Inhibitory cyklin-dependentních kináz a rakovina: využití proteomových studií k určení molekulárních mechanismů a účinnosti nových léčiv

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F07%3A00094564" target="_blank" >RIV/61388971:_____/07:00094564 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/67985904:_____/07:00094564

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Cyclin-dependent kinase inhibitors and cancer: usefulness of proteomic approaches in assessment of the molecular mechanisms and efficacy of novel therapeutics

Popis výsledku v původním jazyce

The chapter resumes all findings obtained up to now in our laboratories in the study of effect of cyclin-dependent kinases inhibitors (CDKI) on cancer cells. In the beginning, the history of discovery of inhibitory effects of trisubstituted purins on cell divisions is introduced. Furthermore, proteomic studies on cancer cells resistant and sensitive to these anti-cancer drugs are described. Results of analyses on transcriptomic level and proteomic level are compared suggesting low correlations between the mRNA and the encoded protein levels. In T-lymphoblastic leukaemia cell line CEM sensitive to CDKI a decrease in level of signalling adaptor Crk-like protein was observed after CDKI treatment. This depression of total level of Crk-like protein and alsoof its phosphorylation at Tyr207 was confirmed by westernblotting. Additional immunohistochemical staining of mouse tumor confirmed in vivo the effect of CDKI on Crk-like levels. These findings proved the importance of proteomic studies

Název v anglickém jazyce

Cyclin-dependent kinase inhibitors and cancer: usefulness of proteomic approaches in assessment of the molecular mechanisms and efficacy of novel therapeutics

Popis výsledku anglicky

The chapter resumes all findings obtained up to now in our laboratories in the study of effect of cyclin-dependent kinases inhibitors (CDKI) on cancer cells. In the beginning, the history of discovery of inhibitory effects of trisubstituted purins on cell divisions is introduced. Furthermore, proteomic studies on cancer cells resistant and sensitive to these anti-cancer drugs are described. Results of analyses on transcriptomic level and proteomic level are compared suggesting low correlations between the mRNA and the encoded protein levels. In T-lymphoblastic leukaemia cell line CEM sensitive to CDKI a decrease in level of signalling adaptor Crk-like protein was observed after CDKI treatment. This depression of total level of Crk-like protein and alsoof its phosphorylation at Tyr207 was confirmed by westernblotting. Additional immunohistochemical staining of mouse tumor confirmed in vivo the effect of CDKI on Crk-like levels. These findings proved the importance of proteomic studies

Druh

C - Kapitola v odborné knize

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Clinical Proteomics. From Diagnosis to Therapy

ISBN

978-3-527-31637-3

Počet stran výsledku

25

Strana od-do

177-202

Počet stran knihy

—

Název nakladatele

Wiley

Místo vydání

Weinheim

Kód UT WoS kapitoly

—